Pembrolizumab anti- PD-1 monotherapy alone cannot induce an effective immunologic response in most GBM patients, probably owing to a scarcity of T cells within the tumor microenvironment and a CD68+ macrophage preponderance [76]. The gene discussed is CD68; the disease is neoplasm.